Fibrosis is a common sequela of cardiovascular disease that results in structural and functional changes. Targeting the subsets of pathogenic cardiac fibroblasts may be an attractive option for reducing morbidity that is associated with heart disease, but the timing, specificity and extent to which fibroblast-targeting therapies might be used is still debated.
- Akitoshi Hara
- Michelle D. Tallquist
